Literature DB >> 8927942

Value of serologic markers for clinical diagnosis and population studies of coeliac disease.

H Ascher1, M Hahn-Zoric, L A Hanson, A F Kilander, L A Nilsson, H Tlaskalová.   

Abstract

BACKGROUND: There is a need for serologic markers in selecting patients with symptoms compatible with coeliac disease for intestinal biopsy and for population screening. Few comparative studies have been done.
METHODS: Sera from 55 patients with coeliac disease and 65 referents, aged between 8 months and 79 years, were investigated. Anti-gliadin, anti-reticulin, anti-endomysium, and anti-jejunal antibodies were measured. The sensitivities, specificities, and positive predictive values for different disease prevalence levels were calculated. Confidence intervals, rarely used in this type of study, were calculated. RESULTS AND
CONCLUSIONS: In most tests the antibody levels were age-correlated. The highest sensitivities in combination with high specificities were found for IgA anti-gliadin antibodies in children less than 5 years of age and IgA anti-endomysium antibodies in older children and adults. These tests were most useful for testing a population with a high disease prevalence, such as patients with gastrointestinal symptoms, although the results for many tests had overlapping confidence intervals. For screening unselected populations with a low disease prevalence, in which a test with maximum specificity is desired, only anti-endomysium antibodies had sufficiently high predictive value to be of practical use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927942     DOI: 10.3109/00365529609031628

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  12 in total

1.  Serologic testing for celiac disease in the United States: results of a multilaboratory comparison study.

Authors:  J A Murray; J Herlein; F Mitros; J A Goeken
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

Review 2.  Endomysial antibody in the diagnosis and management of coeliac disease.

Authors:  M W James; B B Scott
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

3.  Diagnostic approach to a patient with suspected celiac disease: a cost analysis.

Authors:  G C Harewood; J A Murray
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

4.  Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA).

Authors:  P Kucera; D Nováková; M Behanová; J Novak; H Tlaskalová-Hogenová; M Andel
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

5.  New automated immunoassay measuring immunoglobulin A antigliadin antibodies for prediction of celiac disease in childhood.

Authors:  E Grodzinsky; A Ivarsson; P Juto; P Olcén; K Fälth-Magnusson; L A Persson ; O Hernell
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

6.  The changing face of celiac disease.

Authors:  R Lad; K Jacobson
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

7.  A zebra is not always a zebra and a zero is not always a zero.

Authors:  I Krantz; P Nordin; H Wedel; S Blomstrand; H Ascher
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

8.  Influence of infant feeding and gluten intake on coeliac disease.

Authors:  H Ascher; I Krantz; L Rydberg; P Nordin; B Kristiansson
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

9.  Gliadin peptides activate blood monocytes from patients with celiac disease.

Authors:  Jana Cinova; Lenka Palová-Jelínková; Lesley E Smythies; Marie Cerná; Barbara Pecharová; Milos Dvorák; Pavel Fruhauf; Helena Tlaskalová-Hogenová; Phillip D Smith; Ludmila Tucková
Journal:  J Clin Immunol       Date:  2007-01-27       Impact factor: 8.317

Review 10.  Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora.

Authors:  H Tlaskalová-Hogenová; R Stĕpánková; L Tucková; M A Farré; D P Funda; E F Verdú; J Sinkora; T Hudcovic; Z Reháková; B Cukrowska; H Kozáková; L Prokesová
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.